Literature DB >> 16394878

Management of patients with cirrhosis in Southern California: results of a practitioner survey.

Sammy Saab1, Stephen Nguyen, Ayman Ibrahim, John M Vierling, Myron J Tong.   

Abstract

INTRODUCTION: Cirrhosis is an important medical and public health concern. A paucity of data exists on how patients with cirrhosis are managed. Our aims were to determine how cirrhosis is managed and whether current management practices follow established recommendations.
METHODS: A questionnaire was mailed to Southern California Society of Gastroenterology members. Most had practiced for more than 15 years (67%) in a private practice setting (69%). Proportions of physicians who followed established guidelines versus those who had not were compared using chi test.
RESULTS: Hepatitis A, hepatitis B, influenza, and pneumococcus vaccinations were recommended by most respondents. Ninety-one percent of respondents routinely screened patients for hepatocellular carcinoma. A significantly greater proportion of respondents screened for hepatocellular carcinoma using either alpha-fetoprotein or ultrasound every 6 months (P < 0.05). Seventy-six percent recommended antibiotic prophylaxis in patients with prior spontaneous bacterial peritonitis, whereas less than half recommended prophylaxis in patients with ascitic protein fluid <1 g/dL, current variceal bleed, and those on the liver transplant list. Sixty-seven percent of respondents performed screening esophagogastroduodenoscopy upon diagnosis of cirrhosis. Most respondents did not recommend repeating endoscopy in 1 to 2 years if a patient was found to have small varices (P < 0.05), and would repeat an endoscopy if large varices were found (P < 0.05).
CONCLUSION: The management of patients with cirrhosis in the community varied and did not always conform to established guidelines. These results should be confirmed in a larger group of physicians, and the rationales for physicians accepting or rejecting established guidelines should be further assessed.

Entities:  

Mesh:

Year:  2006        PMID: 16394878     DOI: 10.1097/01.mcg.0000196189.65167.53

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  7 in total

1.  Hepatocellular carcinoma surveillance: a national survey of current practices in the USA.

Authors:  Kartik Joshi; Michel Mendler; Robert Gish; Rohit Loomba; Alexander Kuo; Heather Patton; Yuko Kono
Journal:  Dig Dis Sci       Date:  2014-07-16       Impact factor: 3.199

2.  Potential preventability of spontaneous bacterial peritonitis.

Authors:  Saowanee Ngamruengphong; Kenneth Nugent; Ariwan Rakvit; Sreeram Parupudi
Journal:  Dig Dis Sci       Date:  2011-03-11       Impact factor: 3.199

3.  Surveillance for Hepatocellular Carcinoma.

Authors:  Sammy Saab
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-11

4.  Could Adherence to Quality of Care Indicators for Hospitalized Patients With Cirrhosis-Related Ascites Improve Clinical Outcomes?

Authors:  Suong Le; Tim Spelman; Chia-Pei Chong; Phil Ha; Lukas Sahhar; Julian Lim; Tony He; Neel Heerasing; William Sievert
Journal:  Am J Gastroenterol       Date:  2016-01-05       Impact factor: 10.864

5.  Can quality of care for patients with cirrhosis be measured?

Authors:  John T Bassett; Michael L Volk
Journal:  Dig Dis Sci       Date:  2011-06-28       Impact factor: 3.199

6.  Outcomes associated with a mandatory gastroenterology consultation to improve the quality of care of patients hospitalized with decompensated cirrhosis.

Authors:  Rony Ghaoui; Jennifer Friderici; David J Desilets; Tara Lagu; Paul Visintainer; Angelica Belo; Jorge Sotelo; Peter K Lindenauer
Journal:  J Hosp Med       Date:  2014-12-30       Impact factor: 2.960

7.  Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Eimile Dalton-Fitzgerald; Jasmin Tiro; Pragathi Kandunoori; Ethan A Halm; Adam Yopp; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2014-07-11       Impact factor: 11.382

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.